Thomas Jefferson University

Jefferson Digital Commons
Department of Medicine Faculty Papers

Department of Medicine

3-2-2022

Protective benefit of minimally invasive liver surgery for
hepatocellular carcinoma prior to transplant
Simone Khouzam
Duilio Pagano
Marco Barbara
Vito Di Marco
Giada Pietrosi

See next page for additional authors

Follow this and additional works at: https://jdc.jefferson.edu/medfp
Part of the Hepatology Commons, and the Surgery Commons

Let us know how access to this document benefits you
This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital
Commons is a service of Thomas Jefferson University's Center for Teaching and Learning (CTL). The Commons is
a showcase for Jefferson books and journals, peer-reviewed scholarly publications, unique historical collections
from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and interested
readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been
accepted for inclusion in Department of Medicine Faculty Papers by an authorized administrator of the Jefferson
Digital Commons. For more information, please contact: JeffersonDigitalCommons@jefferson.edu.

Authors
Simone Khouzam, Duilio Pagano, Marco Barbara, Vito Di Marco, Giada Pietrosi, Marco Maringhini, Marco
Canzonieri, Sergio Calamia, and Salvatore Gruttadauria

Khouzam et al. Hepatoma Res 2022;8:9
DOI: 10.20517/2394-5079.2021.147

Hepatoma Research

Original Article

Open Access

Protective benefit of minimally invasive liver surgery
for hepatocellular carcinoma prior to transplant
Simone Khouzam1, Duilio Pagano2, Marco Barbara2, Vito Di Marco3, Giada Pietrosi2, Marco Maringhini4,
Marco Canzonieri2, Sergio Calamia2, Salvatore Gruttadauria2,5
1

Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA 19107, USA.
Department for the Treatment and Study of Abdominal Diseases and Abdominal Transplantation, IRCCS-ISMETT (Istituto di
Ricovero e Cura a Carattere Scientifico-Istituto Mediterraneo per I Trapianti e Terapie ad Alta Specializzazione), UPMC
(University of Pittsburgh Medical Center), via E. Tricomi 5, Palermo 90127, Italy.
3
Sezione di Gastroenterologia e Epatologia, Dipartimento Biomedico di Medicina Interna e Specialistica, University of Palermo,
Palermo 90128, Italy.
4
Medicina Interna, Università di Palermo/ISMETT, Via del Vespro 129, Palermo 90127, Italy.
5
Department of Surgery and Medical and Surgical Specialties, University of Catania, Catania 95124, Italy.
2

Correspondence to: Prof. Salvatore Gruttadauria, Department for the Treatment and Study of Abdominal Diseases and
Abdominal Transplantation, IRCCS-ISMETT (Istituto di Ricovero e Cura a Carattere Scientifico-Istituto Mediterraneo per I
Trapianti e Terapie ad Alta Specializzazione), UPMC (University of Pittsburgh Medical Center), Palermo 90127, Italy.
E-mail: sgruttadauria@ISMETT.edu
How to cite this article: Khouzam S, Pagano D, Barbara M, Di Marco V, Pietrosi G, Maringhini M, Canzonieri M, Calamia S,
Gruttadauria S. Protective benefit of minimally invasive liver surgery for hepatocellular carcinoma prior to transplant. Hepatoma
Res 2022;8:9. https://dx.doi.org/10.20517/2394-5079.2021.147
Received: 21 Dec 2021 First Decision: 14 Jan 2022 Revised: 28 Jan 2022 Accepted: 22 Feb 2022 Published: 2 Mar 2022
Academic Editor: Guang-Wen Cao Copy Editor: Xi-Jun Chen Production Editor: Xi-Jun Chen

Abstract
Aim: The purpose of this study is to assess the benefit of laparoscopic liver resection (LLR) for hepatocellular
carcinoma (HCC) given recurrence and future need for liver transplantation (LT).
Methods: Data on liver resections were gathered from the Istituto di Ricovero e Cura a Carattere ScientificoIstituto Mediterraneo per i Trapianti e Terapie ad alta specializzazione (IRCCS-ISMETT) from 2003-2021. A
retrospective analysis of 1408 consecutive adult patients who had a liver resection was performed with
categorization based on the underlying disease process. A sub-analysis studied the 291 patients who had an LLR
with an intention to transplant approach after LLR.
Results: From 2012 to 2020, ISMETT’s mean annual LLR rate was 45%. Data suggests that a laparoscopic
approach to iterative surgical treatment for HCC has demonstrated protective benefits. Compared to open surgery
or LT, LLR is protective against the risk of de-listing, post-transplant patient death, tumor recurrence, adhesions,
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and bleeding in a cirrhotic patient. Kaplan Meier’s analysis showed no difference between post-LT survival curves
for those with prior open abdominal surgery or LLR (P = 0.658).
Conclusion: Laparoscopic surgery has important protective advantages over laparotomy surgery for the surgical
treatment of HCC, particularly since treatment is not always curative. LLR can be considered a bridge therapy for
transplantation, ensuring less crowding of waiting lists, a desirable condition in areas of donor storage.
Keywords: Laparoscopic, liver resection, hepatocellular carcinoma, minimally invasive liver surgery

INTRODUCTION
The clinical entity of hepatocellular carcinoma (HCC) is responsible for 80%-90% of primary liver cancers,
and it is the third leading cause of cancer-related death worldwide[1]. The challenge in management arises
from being able to deliver a curative treatment without precipitating further liver decompensation. The
surgical options for curative treatment are defined as liver resection (LR), liver transplantation (LT), and
ablation modalities. These treatments have been associated with a median overall survival of ≥ 60 months,
with a 5-year survival rate approaching 70%[2]. However, HCC recurrence (RHCC) develops in nearly 70%
of patients within five years after initial resection.
While LT is the definitive treatment of these curative treatment options, the possibility of recurrence,
waiting list times, and limited organ supply require consideration of LR prior to LT. Italy’s organ allocation
system uses the ISO score, a blended model of urgency, utility, and transplant benefit[3,4]. Given the high
likelihood of RHCC, post-transplant recurrence and outcomes must be considered[5,6]. It is necessary to
delineate the first-line laparoscopic surgical approach with the second-line surgical options for RHCC,
particularly those requiring LT. Here we report a series of HCC patients’ management and treatments at the
ISMETT center (Mediterranean Institute for Transplantation and Highly Specialized Therapies) with an
intention to transplant approach after laparoscopic liver resection (LLR).

METHODS
Our retrospective analysis studied 1408 adult patients who had a liver resection at our institute from January
2003 until November 2021, with categorization based on the underlying disease process. The etiologic
categories were HCC, colorectal liver metastasis, non-colorectal liver metastasis, biliary cancer, benign
tumor, living liver donor, trauma, and others. In addition, a sub-analysis studied the 291 patients who had
an LLR, also known as minimal invasive liver surgery (MILS), were categorized in the same manner as the
larger cohort, except there was no categorization of trauma or other as MILS is not indicated in those
circumstances. All data were collected using the electronic database and processed retrospectively. The
diagnosis of HCC was made in the period before being listed for LT following the criteria of the main
AASLD and EASL-EORTC Clinical Practice Guidelines[7,8].
The surgical treatment option was made after a careful multidisciplinary evaluation of the patient and
considering staging, tumor location, and residual liver function[9]. All patients in the study were included in
the list after radiological confirmation of compliance with the Milan criteria (single nodule ≤ 5 cm or up to 3
nodules each ≤ 3 cm, in the absence of macrovascular infiltration and distant metastases). In some doubtful
cases, it was also necessary to perform a biopsy examination. Patients with a diagnosis of HCC initially
outside the Milan criteria were included in the list only after being treated with loco-regional techniques
(bridge-therapy), managing to obtain a down-staging of the HCC, thus falling within the Milan criteria, and
after maintaining the criteria for at least six months. Bridge-therapy techniques were limited to transarterial
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chemoembolization and microwave thermal ablation with no surgical intervention until they were within
the Milan criteria.
From the inclusion in the waiting list time until the moment of LT, all patients underwent clinicallaboratory checks every three months, with blood chemistry tests and alpha-fetoprotein (AFP) level, and
instrumental every six months by means of abdominal computed tomography (CT) with contrast medium
and/or magnetic resonance imaging (MRI) with hepato-specific contrast agent. After LT, all patients
underwent a follow-up protocol that included AFP levels, chest x-ray and abdomen CT with contrast
medium, and/or MRI with hepato-specific contrast medium every six months. In case of ascertained or
suspected recurrence of intrahepatic and/or extrahepatic HCC, other investigations were performed: liver
MRI, chest CT, bone scan, ultrasound-guided biopsy, or positron emission tomography. The survival curve
between LT patients who underwent pre-transplant LLR, and any open abdominal surgery was calculated
according to the Kaplan-Meier method, with the log-rank - test used to compare the curves. Data were
analyzed using SPSS version 22.0 (SPSS Inc., Chicago, IL, USA) and MedCalc (MedCalc Software,
Mariakerke, Belgium).

RESULTS
Study population

Of the 1408 patients who underwent liver resection, 291 underwent a minimally invasive approach and 1117
underwent an open approach. For the entire liver resection group, 29% had HCC, 31% had colorectal liver
metastasis, 13% had benign tumors, 12% were living liver donors, 9% had biliary cancer, 5% had noncolorectal liver metastasis, 1% had trauma, and 0% had other indications.
Comparative in the MILS cohort, 53% had HCC, 19% had benign cancer, 14% had colorectal liver
metastasis, 7% had biliary cancer, 4% were living liver donors, and 3% had non-colorectal liver metastasis as
the indication for liver resection. Of note, the HCC indication was nearly double in the MILS cohort
compared to the overall total group.
HCC laparoscopic liver resections

HCC was the main indication for liver resection in both groups, with 63% (n = 258) performed open vs. 37%
performed minimal invasively (n = 149) as the average rate from 2003 to 2021. To better assess the current
rate of MILS resection, the resection rate was separated into two time periods: 2003 to 2011 and 2012 to
2020. The mean annual rate from 2003 to 2011 was 7%, whereas it was 45% from 2012 to 2020, with a
significant inflection point in 2012 [Figure 1].
Of the laparoscopic hepatic resections for HCC (n = 149), hepatitis C virus accounted for 67% of the
primary cause of HCC with hepatitis B virus at 12%, non-alcoholic steatohepatitis at 12%, alcohol at 5%, and
other at 4%. Furthermore, the types of resections were classified as either major or minor. Major resections
are defined as any resection of three contiguous segments, including open right hepatectomy (n = 3) and
laparoscopic left hepatectomy (n = 1). Minor resections included bisegmentectomy (n = 8), not including
left lobectomy (n = 1), segmentectomy (n = 15), wedge resection of 2 nodules (n = 12), and wedge resection
of 1 nodule (n = 110). The segments involved in these types of resections appeared to be evenly distributed
aside from segment 1, which was never involved. Segment 2 accounted for 21% (n = 31), segment 3 accounts
for 19% (n = 29), segment 4 account for 13% (n = 19), segment 5 account for 22% (n = 33), segment 6
accounted for 25% (n = 38), and segment 7 accounted for 19% (n = 28). As some HCC resections involved
multiple segments, each segment was included in the count.
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Figure 1. We present the annual percentages of laparoscopic HCC resection at our center with the mean annual rate calculated from
the period of 2003 to 2011 as 7% and 2012 to 2020 as 45%. HCC: Hepatocellular carcinoma.

No differences were detected in terms of patient survival curve between LT patients who underwent pretransplant LLR and any open abdominal surgery, such as LR or colectomy, according to the Kaplan-Meier
analysis (P = 0.658, Figure 2). The most common LR complication noted was a biliary leak (n = 4; 1.37%). In
the LLR cohort, there was only one grade B biliary leak (0.07%), whereas in the open cohort, there were 3
biliary leaks (1.16%), of which there was 1 grade A, 1 grade B, and 1 grade C biliary leak.
HCC Microwave thermal ablation

At our center, 87 patients with HCC underwent microwave thermal ablations from 2003 to 2021. This
treatment option is an alternative to surgical resection or liver transplant for those who do not qualify for
surgical resection or transplant due to comorbid risk factors, disease progression, or do not wish for a
surgical procedure. The HCC lesions treated were found in all segments: segment 1 (n = 1), segment 2
(n = 4), segment 3 (n = 4), segment 4 (n = 11), segment 5 (n = 8), segment 6 (n = 12), segment 7 (n = 24),
segment 8 (n = 23).
HCC recurrence treatment options

Despite initial hepatic resection with preserved liver function, the majority of patients had a recurrence of
HCC. From 2013 to 2021, 563 patients had a first-line surgical treatment for HCC, with 31 patients
receiving second-line surgical treatment. A minimally invasive approach was taken in 178 out of the 563
first-line approaches [Figure 3]. Of the 14 patients who underwent a subsequent LT, there were 9 who
previously underwent LR.

DISCUSSION
Liver resection and transplantation are the best treatments in terms of radicality for HCC and its
recurrences[10]. Given the high relapse rate, it is essential to consider the hepatocellular carcinoma resection
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Figure 2. Time from MILS to liver transplant and Kaplan Meier curve comparing overall survival post-OLT after previous open surgery
or previous MILS. OLT: Orthotopic liver transplant; MILS: minimally invasive liver surgery.

Figure 3. Diagram of first- and second-line surgical treatments for HCC from 2013 to 2021. HCC: Hepatocellular carcinoma; OLT:
orthotopic liver transplantation.

as the first potential series intervention. Laparoscopic surgery has become the gold standard for treating
HCC since the 2010s and changes in Italian national guidelines[11-16]. The inflection point of LLR in 2012 at
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our center correlates with the timeframe of the acceptance of LLR specifically for HCC patient outcomes.
Moreover, reducing abdominal wall trauma with less resulting pain, less bleeding, and ascetic are wellknown advantages of laparoscopy. Another significant advantage of laparoscopic surgery is reducing
postoperative adhesions, making subsequent surgical approaches simpler and safer[17]. The surgical
indication for laparoscopy can be extended to more complex patients with more advanced liver disease.
Still, LR, when feasible, and LT, when indicated, remain the best radical treatments even in the treatment for
RHCC. For this reason, it becomes increasingly important to perform LLR whenever possible. LLR
determines fewer postoperative adhesions and poses the best conditions for resection and transplant
reoperations.
LLR in advanced cirrhosis is safe and provides optimal long-term survival for select patients with HCC.
While the benefits of LLR in Child-Turcotte-Pugh (CTP) cirrhotic patients for HCC have been well known,
it still remains unclear for Child-Pugh B cirrhosis, the superior benefits of MILS over laparotomy HCC
resection were recently demonstrated for patients without preoperative portal hypertension and score of
CTP B7 cirrhosis[18]. By using the IWATE classification, the complexity and extent of LR are
determined[19,20]. Long-term survival is most impacted by patient comorbidities, age, degree of underlying
liver disease, and high-quality oncologic surgery with > 2 comorbidities, older age, grade 3-4 disease,
regional lymph node metastasis (N1), and hepatectomy with microscopic exposure of tumor margins (R1)
as predictors of worse overall survival[21-27]. RHCC can be developed in entirely different settings, and it
depends on the first-line therapy which was chosen. An immunosuppressive regimen needs to be adopted
in LT recipients, and the presence of extrahepatic disease can dramatically direct patients to systemic
therapies. LR and thermal ablation remain the surgical choices that offer a high probability of complete and
potentially curative response for HCC recurrence[9,27-29].
Clinical, pathological, and genetic factors affect and predict HCC progression. Clinically higher serum
bilirubin levels, in addition to pathological evidence of more nodules and larger nodules, were predictors of
HCC recurrence. While at a genetic level, loss of phosphate and tensin homolog loci heterozygosity has
been demonstrated with a lower risk of HCC recurrence and a protective effect of specific AI mutations for
the risk of HCC recurrence[30-32]. Given the recurrence rates of HCC, the pathways of iterative surgical
treatment must be considered. The role of MILS is of particular interest as a bridge for salvage liver
transplantation (SLT). An intention-to-treat survival analysis demonstrated that MILS resection was
associated with a lower risk of SLT failure and death after SLT vs. open surgery (74% and 71% risk
reduction, respectively), mitigating the higher operative morbidity in SLT seen in previous studies. These
results were confirmed with a propensity score matching a balanced population for the type of resections
and tumor size, but most laparoscopic LRs were wedge or segmentectomies[33].
The data collected from our institute confirm the advantages of laparoscopic surgery in the first surgical
treatment of HCC. In fact, over 80% of patients who have undergone reoperation had undergone a first
laparoscopic operation even though there are fewer laparoscopic interventions than laparotomies overall.
This underlines that the first laparoscopic approach guarantees better chances of reoperation. A similar
observation can be made for patients who have a better chance of transplant due to their age and clinical
conditions. However, it is important to consider the small sample size of OLT as a second-line surgical
treatment after MILS. This number is expected to grow due to the increased prevalence of MILS and the
changes in Italy’s organ allocation score since 2018[4,34-36].
Contrary to the past evidence, prior surgery does not represent an absolute contraindication to liver
transplantation, especially if the first surgery is laparoscopic. In our institute, the vast majority of patients
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transplanted after a first surgical treatment of hepatocellular carcinoma had performed laparoscopic
surgery. The adhesions found intraoperatively in no case compromised or complicated the hepatectomy
during transplantation. This allows us to consider laparoscopic liver resection as a bridge therapy for
transplantation, ensuring less crowding of waiting lists, a desirable condition in certain areas dealing with a
shortage of donors. Although the number of transplants performed in patients already operated on is very
small, there are many patients who, undergoing LLR, will have no contraindications or difficulties in
carrying out a transplant procedure.
Laparoscopy, compared to an open approach, is associated with similar oncological results and better shortterm outcomes. Minimally invasive liver surgery preserves the abdominal wall, minimizes peritoneal
trauma, and decreases overall complication rates. In addition, there are fewer liver complications such as
ascites and liver failure, decreased pedicle clamping time, and shorter postoperative hospital stays compared
to open LRs[17]. For HCC patients, LLR prior to LT provides the benefit of significantly reduced de-listing
and death after LT.
In conclusion, liver resection is the gold-standard treatment for HCC, second to liver transplantation, but
long-term outcomes post-resection are poor due to high recurrence rates. As for intrahepatic recurrence,
repeat hepatectomy is still considered to be one of the most important potential curative therapies. The
possibility of needing to reoperate a patient who has already undergone hepatic-resective surgery for HCC
is high. For this reason, it becomes increasingly important to perform laparoscopic surgery whenever
possible. Laparoscopy determines fewer postoperative adhesions, thus posing the best conditions for both
hepatic-resective and transplant reoperation.
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